Archives

Use the basic search or click on advanced for more search options.

Advanced Search Basic Search Advanced Search

Publications

Section

Select publication to see the relevant sections.

Publication Date

    E.g., 2018-09-19
    E.g., 2018-09-19

Archive Search

Pages

13 results
12:00 AM, Nov 02, 2009  |  BC Week In Review | Clinical News  |  Clinical Results

MKC1106-MT: Phase I data

Determine pMEL- TYR plasmid level in the blood by PCR analysis, determine target antigen expression (Melan A
12:00 AM, Apr 28, 2008  |  BC Week In Review | Clinical News  |  Clinical Status

CYT004-MelQbG10: Phase IIa start

  Molecular target: Not applicable   Description: Vaccine consisting of a modified fragment of the Melan-A
12:00 AM, Dec 03, 2007  |  BC Week In Review | Clinical News  |  Clinical Results

CYT004-MelQbG10: Phase IIa data

  Molecular target: Not applicable   Description: Vaccine consisting of a modified fragment of the Melan-A
12:00 AM, Sep 03, 2007  |  BC Week In Review | Clinical News  |  Clinical Status

ImmuFact IMP321: Phase I started

an adjuvant. After undergoing chemotherapeutic lymphodepletion and adoptive T cell transfer, patients will receive a Melan-A
MART1 vaccine in combination with both IMP321 and incomplete Freund's adjuvant. Immutep S.A. , Orsay …
12:00 AM, Jun 12, 2006  |  BC Week In Review | Clinical News  |  Clinical Results

Hi-8 MEL: Phase I/II data

6 months. About 7 of 8 patients with tumor response showed immune response to Melan-A
12:00 AM, Oct 24, 2005  |  BC Week In Review | Clinical News  |  Clinical Status

CYT004-MelQbG10: Phase IIa started

  Molecular target: NA   Description: A vaccine consisting of a modified fragment of the Melan-A
12:00 AM, Jun 09, 2003  |  BC Week In Review | Clinical News  |  Clinical Results

Dendritic cell cancer vaccine: Phase I/II

  Description: Autologous dendritic cells (DCs) transduced with adenovirus carrying genes for melanoma rejection antigens Melan A/MART-1 …
12:00 AM, Jan 13, 2003  |  BC Week In Review | Clinical News  |  Clinical Results

Ex vivo melanoma vaccine: Phase I/II

Immune cells   Description: Dendritic cells transduced with virus vectors encoding melanoma tumor antigens MELANA/ MART1
12:00 AM, Nov 18, 2002  |  BC Week In Review | Clinical News  |  Clinical Results

Adoptive cell therapy: Phase I

Description: Therapy involving the ex vivo selection and expansion of T cells targeting melanoma antigens MART1
Melan-A and gp100   Indication: Treat metastatic melanoma   Endpoint: Safety, tumor response   Status …
12:00 AM, Apr 15, 2002  |  BC Week In Review | Clinical News  |  Clinical Status

MelanA/MART 1 and gp100 vaccines: GZMO will enroll an additional 8 patients in a dose-escalation U.S. Phase I/II trial after completing enrollment of an intende

Target: MelanA/MART 1 and gp100 antigens   Description: Adenovirus vector encoding melanoma tumor antigens MELANA/ MART1

Pages